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The “Highway” to PeripheryWe read with interest the study of Eitel et al. (1) about the AIDA
STEMI (Abciximab i.v. Versus i.c. in ST-Elevation Myocardial
Infarction) trial, regarding infarct size. The study shows an inter-
esting result: Microvascular Obstruction (MO) and infarct size did
not signiﬁcantly differ between intravenous versus intracoronary
administration of abciximab.
The glycoprotein IIb/IIIa inhibitors (GPI) can be effective only
on fresh thrombus, lowering the thrombus burden and dis-
aggregating embolized platelet microaggregates. Recently, 1 study
(2) has shown the presence of old thrombus in 40% of patients with
ST-segment elevation myocardial infarction. This would be one of
the mechanisms underlying the inconsistent beneﬁt of GPIs.
Another potential mechanism might be the lack or the short
contact time between the GPI, thrombus, and embolized micro-
aggregates. In the study of Bellandi et al. (3), with downstream
GPI administration, a signiﬁcant beneﬁcial effect on MO and
infarct size occurred. In the INFUSE-AMI (Intracoronary
Abciximab Infusion and Aspiration Thrombectomy in Patients
Undergoing Percutaneous Coronary Intervention for Anterior ST
Segment Elevation Myocardial Infarction) trial (4), abciximab was
administered through the ClearWay catheter, which might be
equivalent with a pre-dilation. In addition, the effect of abciximab
was targeted mostly to the thrombus. There was no difference on
MO, but a modest reduction in infarct size occurred. In a study
recently published, our group used a Twin-Pass catheter for
downstream and intrathrombus GPI delivery (5). There were no
signiﬁcant differences on MO and infarct size, but there was
a trend toward better MO results with intracoronary GPI. The
downstream administration of GPIs achieves higher local drug
concentrations and a longer contact on microaggregates.
The cases with old thrombus could be associated with more
extensive MO (2). These patients may beneﬁt from intracoronary
thrombolytic drugs, as shown by Sezer et al. (6).*Adrian C. Iancu, MD, PhD
Camelia Ober, MD
*“Niculae Stancioiu” Heart Institute
Motilor Str, No. 19-21
400001, Cluj-Napoca
Romania
E-mail: motu_iancu@yahoo.com
http://dx.doi.org/10.1016/j.jacc.2013.04.052REFERENCES
1. Eitel I, Wöhrle J, Suenkel H, et al. Intracoronary compared with
intravenous bolus abciximab application during primary percutaneous
coronary intervention in ST-segment elevation myocardial infarction:
cardiac magnetic resonance substudy of the AIDA-STEMI trial. J Am
Coll Cardiol 2013;61:1447–54.
2. Kramer MC, van der Wal AC, Koch KT, et al. Presence of older
thrombus is an independent predictor of long-term mortality in patients
with ST-elevation myocardial infarction treated with thrombus aspira-
tion during primary percutaneous coronary intervention. Circulation
2008;118:1810–6.
3. Bellandi F, Maioli M, Gallopin M, et al. Increase of myocardial salvage
and left ventricular function recovery with intracoronary abciximab
downstream of the coronary occlusion in patients with acute myocardial
infarction treated with primary coronary intervention. Cathet Cardiovasc
Interv 2004;62:186–92.
4. Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab
and aspiration thrombectomy in patients with large anterior myocardial
infarction: the INFUSE-AMI randomized trial. JAMA 2012;307:1817–26.
5. Iancu A, Ober C, Bondor CI, Cadis H. Microvascular effect of intra-
coronary eptiﬁbatide in acute myocardial infarction. Cardiology 2012;
123:46–53.
6. Sezer M, Oﬂaz H, Gören T, et al. Intracoronary streptokinase after
primary percutaneous coronary intervention. N Engl J Med 2007;356:
1823–34.ReplyWe thank Drs. Iancu and Ober for their interest in our work (1).
We agree that timing of glycoprotein IIb/IIIa inhibitor adminis-
tration is an important factor. A recent meta-analysis comparing
intravenous versus intracoronary abciximab application found
a trend toward a greater efﬁcacy with intracoronary abciximab with
an ischemic time <3 h (2). This ﬁnding may be partly related to the
fast-evolving process of thrombus formation during an acute
coronary occlusion. Indeed, a recent study demonstrated that
platelet and ﬁbrin contents of the occlusive thrombus are highly
dependent on ischemia time, which may have a direct impact on
the efﬁcacy of glycoprotein IIb/IIIa inhibitors (3). However, in the
AIDA STEMI trial (Abciximab i.v. Versus i.c. in ST-elevation
Myocardial Infarction) and the cardiac magnetic resonance sub-
study there was no beneﬁt with intracoronary abciximab application
even in patients reperfused early after symptom onset (<3 h) (1,4).
We also agree that the short contact time between the glyco-
protein IIb/IIIa inhibitor with plaque/thrombus components might
have inﬂuenced the results of our study. In the AIDA STEMI trial
abciximab was injected through the guiding catheter after wiring of
the infarct-related artery (1,4). Although easy to implement in
clinical practice, this way of delivery may be suboptimal in selected
patients due to inadequate thrombus penetration of abciximab and
possible retrograde washout into the ascending aorta. Novel
application systems such as dedicated perfusion catheters may exert
superior efﬁcacy by maintaining a high local abciximab concen-
tration, thereby providing an optimal contact between the plaque/
thrombus components and the drug. However, it is important to
